Table 3.

TVEC Clinical Trials in Melanoma.

Therapy	Phase (Enrollment)	Primary Outcomes
TVEC Monotherapy	I (n = 30)	Established dosing regimen
TVEC Monotherapy	II (n = 50)	ORR = 26%, CR = 16%
TVEC v. GM-CSF	III (n = 436)	TVEC improved DRR v. GM-CSF (16% v. 2%, p < 0.001)
Neoadjuvant TVEC v. Immediate Resection	II (n = 150)	Enrollment completed May 2017, results pending
Ipilimumab +/− TVEC	Ib/II (n = 198)	Addition of TVEC to Ipilimumab improved ORR (39% v. 18%, p = 0.002)
Pembrolizumab +/− TVEC	Ib/III (n = 660)	Ib (n = 21) demonstrated tolerability and ORR = 57% with combo; phase III enrolling
TVEC + Dabrafenib and Trametinib	Ib (n = 20)	Enrolling